|
FDA Lifts Partial Clinical Hold on Genmab Cancer Drug
Danish drugmaker Genmab can resume patient enrollment in trials of zalutumumab as a treatment of head and neck cancer because the FDA lifted a partial clinical hold on the research.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives